Pharmacokinetic Comparison of FYB206 and Pembrolizumab in Adjuvant Treatment of Stage IIB, IIC, or III Melanoma Post-Resection

The primary objective of this study is to evaluate the **pharmacokinetic similarity** of FYB206 in comparison with Keytruda in patients with resected Stage II or Stage III **melanoma**. This assessment is clinically relevant as it aims to determine whether FYB206 can provide a comparable pharmacokinetic profile to Keytruda, which is crucial for ensuring similar therapeutic efficacy and safety in the adjuvant treatment of patients with Stage IIB, IIC, or III melanoma following complete resection.

The clinical trial involves a total of **48 participants** diagnosed with **melanoma**, specifically those requiring adjuvant treatment following complete resection of Stage IIB, IIC, or III melanoma. The study population includes both male and female subjects, with an age range that encompasses both adults and older adults. Participants were selected based on their health status, which includes a history of melanoma, and the trial does not exclude vulnerable populations. Lifestyle factors such as diet, physical activity, or habits are not specified in the available data. The selection criteria for the trial population are not detailed, as the sponsor has not provided this information.

The clinical trial is designed to assess the **pharmacokinetic** similarity of FYB206 in comparison with Keytruda in patients with resected Stage II or Stage III melanoma. This trial is structured as a Phase 2, randomized, double-blind, controlled study. The estimated recruitment start date is June 30, 2024, with an anticipated end date of June 30, 2026. Participants will be involved in the study for the duration of the trial, which spans approximately two years.

The sequence of study visits begins with an inclusion visit, also known as the screening visit, where potential participants are evaluated against the inclusion and exclusion criteria to determine eligibility. Following successful screening, participants will be randomized to receive either FYB206 or Keytruda. Throughout the trial, participants will attend regular follow-up visits to monitor their response to the treatment and to collect pharmacokinetic data. These visits are crucial for ensuring participant safety and for the collection of data necessary to meet the trial's objectives. The trial will conclude with an end-of-study visit, where final assessments will be conducted to evaluate the overall outcomes of the treatment.

Participants are expected to remain in the study for its entire duration unless specific conditions necessitate early termination. Such conditions may include adverse reactions to the treatment, withdrawal of consent, or any other medical reasons deemed significant by the study investigators. The trial's design and procedures are meticulously planned to ensure the collection of reliable data while maintaining the safety and well-being of all participants.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to commence recruitment on June 30, 2024, with an estimated completion date of June 30, 2026. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured methodology for measuring, collecting, and analyzing these efficacy parameters, adhering to the standards expected in clinical research. The trial's design and execution will ensure that data collection is systematic and that analysis is conducted using appropriate statistical methods to determine the efficacy of the intervention under investigation. The trial phase indicates a focus on evaluating the treatment's effectiveness and further understanding its therapeutic potential.